Immunome, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 106.81 million compared to USD 36.9 million a year ago. Basic loss per share from continuing operations was USD 5.38 compared to USD 3.09 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.61 USD | -0.89% | +12.52% | +45.33% |
May. 02 | Immunome, Inc. Appoints Kinney Horn as Chief Business Officer | CI |
Apr. 30 | JPMorgan Starts Immunome With Overweight Rating, $24 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.33% | 944M | |
+8.48% | 105B | |
-1.02% | 104B | |
+5.59% | 22.94B | |
-12.33% | 22.34B | |
-6.45% | 19.25B | |
-39.98% | 17.08B | |
-9.07% | 16.96B | |
+7.24% | 14.16B | |
+39.48% | 12.63B |
- Stock Market
- Equities
- IMNM Stock
- News Immunome, Inc.
- Immunome, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023